Bli medlem
Bli medlem

Du är här


Bluefish Pharmaceuticals AB: Extension of convertible debt of SEK 21.7 million

"Maintained conditions with new maturity 30 June 2017"

During 2011, Bluefish issued the convertible debt serie 2011/2014 with
maturity 30 June 2014 of a total amount of SEK 60 million .

At the extraordinary general meeting on 5 July 2013, it was resolved
to offer all holders of the convertible debt 2011/2014 the
possibility of either extend their holding at maintained conditions
but with new maturity 30 June 2017, or to convert to B shares at a
price of 5 SEK per share.

The offer to extend the holding with new maturity 30 June 2017 has
been accepted by holders of the convertible debt equivalent to an
amount of SEK 21.7 million. Another SEK 20 million have been
converted to B shares. The remaining amount of SEK 18.4 million will
be repaid at maturity on 30 June 2014.

Full conversion of the convertible debt with maturity 30 June 2017
equivalent to a nominal amount of SEK 21.7 million would increase the
company's share capital by not more than 578 666,60 SEK through the
issuance of not more than 2 893 333 B shares.

For more information, contact
Karl Karlsson, President & CEO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Susanna Urdmark, CFO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00

About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the
company was founded in 2005. Bluefish focuses on the development,
manufacture and sale of generic pharmaceuticals. The company conducts
marketing operations in a large number of European markets and is
expanding into territories outside Europe. The product portfolio
consists of a total of 80 products and is growing.


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.